The Company entered into a License Agreement with Novartis granting global ... subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area.

Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) ...

The Watertown biotech is already working with pharma giants Astellas Pharma Inc. and Novartis AG to engineer ... develop treatments for central nervous system and liver-associated diseases.

According to this report, the central nervous system (CNS) therapeutics market ... Pharma firms like GSK, AstraZeneca and Novartis have announced closures of neuroscience divisions in the last ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ...

Q3 2024 Earnings Call Transcript October 31, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.87, expectations were $-0.93. Operator: Good day, everyone, and welcome ...

AGTC’s development foci are centred on rare ophthalmic, otologic, and central nervous system (CNS ... of certain milestones related to AGTC’s products. Chief investment officer of Syncona ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...

For Boehringer, the deal adds to a broad pipeline in schizophrenia that spans both pharmacological and digital therapeutic (DTx) products ... s global head of CNS discovery research.

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...